Dogs suffering from chronic, acute, or seasonal itching and inflammation can soon benefit from a new dermatology drug.
Elanco Animal Health Incorporated has announced the U.S. Food and Drug Administration (FDA) approval of Zenrelia, their proprietary once-daily oral JAK inhibitor for control of pruritus associated with allergic dermatitis and control of atopic dermatitis in dogs at least 12 months of age.
The animal health company conducted a randomized, double-blind study of 338 client-owned dogs with confirmed atopic dermatitis across 25 study sites in four countries. The study reportedly shows one daily dose of the oral medication is at least as effective as the market incumbent JAK inhibitor at the primary end point on Day 28.
Dogs should be up to date on vaccinations prior to starting Zenrelia. For more information, visit the Elanco website.